The molecular origin of X-linked hyper IgM syndrome has recently been identified as a defect in the ligand of CD40, gp39, a protein expressed on the surface of activated T cells.
Introduction
X-linked hyper IgM syndrome (X-HIM)1 is a primary immunodeficiency disorder characterized by hypogammaglobulinemia and recurrent bacterial infections. Affected males have normal levels of circulating T and B cells, normal to elevated levels of serum IgM, low levels of IgG, and nondetectable levels of IgE or IgA. As a result of the impaired immune response, affected males are susceptible to bacterial and opportunistic infections, generally beginning at the end of the first or early in the second year of life. The clinical manifestations of X-HIM include recurrent upper respiratory tract infections, pneumonia, diarrhea, otitis media, occasional lymphoid hyperplasia, and frequent neutropenia. In addition, it appears that affected males, as a group, are unusually susceptible to Pneumocystis carinii. Though intravenous immunoglobulin infusions are effective, X-HIM patients may succumb to opportunistic infection early in life or to lymphomas or other malignancies during childhood or early adulthood (1) .
The molecular basis of X-HIM has recently been shown to result from defects in the T cell surface protein gp39. Studies designed to elucidate the role of lymphocyte cell surface proteins in T cell-B cell interactions have previously led to the identification and characterization of the gp39/CD40 ligand receptor pair as important in B cell proliferation and antibody isotype switching (2) (3) (4) . Gp39 (CD40L, Trap) is a type II membrane glycoprotein expressed on the surface of T cells 6-8 h after activation (5) (6) (7) (8) . CD40 is a type I membrane glycoprotein (9) constitutively expressed by B cells (2) , monocytes (10) , follicular dendritic cells, basal and thymic epithelial cells (11, 12) , and some tumor-derived cell lines (13) . Stimulation of the CD40 receptor with anti-CD40 monoclonal antibodies (mAbs) or recombinant gp39 in conjunction with IL-4 or IL-10 results in B cell proliferation and the production of IgE or IgA, IgG and IgM immunoglobulin isotypes, respectively (3, 14-18) (S. Nonoyama, unpublished observations). Stimulation of CD40 on monocytes and thymic epithelial cells modulates cytokine secretion by these two cell types (10) .
Two independent approaches led to the determination that defects in the gp39 gene are the molecular basis for X-HIM. In the first approach, the role of the gp39/CD40 interaction was examined in several primary immunodeficiency disorders, including common variable immunodeficiency (CVI), X-linked agammaglobulinemia (XLA) and X-HIM. These studies demonstrated that peripheral blood T cells from X-HIM patients fail to express detectable levels of functional gp39 protein following in vitro activation, yet these cells express levels of mRNA encoding gp39 within the normal range. Sequencing of gp39 cDNAs obtained from X-HIM patients showed that they contained point mutations. It was subsequently shown that these point mutations abolished the ability of gp39 to bind to CD40 and drive B cell proliferation and isotype switching (15) . In a different approach, the gene encoding gp39 was found to be localized to the same area of the X chromosome as the gene responsible for X-HIM. This initiated an examination of the gp39 protein levels expressed by activated T cells from patients with X-HIM. The observation that the T cells from affected patients expressed no functional gp39 led to DNA sequencing experiments and the demonstration of mutations in the gp39 gene in individuals with X-HIM (19) (20) (21) (22) .
Knowledge of the genetic basis of HIGM I allows examination of the possibility of nonrandom X chromosome inactivation in female carriers and sets the stage for the development of methodologies for the detection of female carriers and prenatal diagnosis. Here we describe the detailed pedigree analysis of three families with affected males, which allowed us to identify five female carriers of HIGM 1. We investigated the inactivation of the defective X chromosome in these female carriers by immunofluorescence staining, to identify the fraction of in vitro activated T cells expressing functional gp39, and by DNA sequencing of multiple independent cDNA clones obtained by PCR.
Methods
Patients and their families. C.D., the only affected male in Family 1, is a 15-yr-old boy with a history of frequent bacterial infections since infancy, moderately elevated IgM, low IgG, and absent IgA. His halfsister, mother, and two maternal uncles are healthy and alive. The four brothers of his maternal grandmother were healthy through adulthood; two are still alive.
J.W., the second son of a healthy mother, developed P. carinii during infancy and subsequently had recurrent bacterial infections. His serum IgM is persistently elevated, IgG is low, and IgA is absent. At 12 years of age, he developed immune complex disease after a viral infection, and developed severe renal disease, resulting in therapy-resistant hypertension. He died at the age of 25, of cerebral hemorrhage. His older brother died at 5 mos old of P. carinii; serum IgM was elevated. The maternal grandparents were healthy and handled infections well.
Five of six brothers in Family 3 are affected with X-HIM. One boy died during infancy of P. carinii. The other four brothers have recurrent bacterial infections; two have neutropenia and all show elevated serum IgM, low IgG, and absent or low IgA. The mother and five maternal aunts are asymptomatic. Together, the five maternal aunts have 16 boys and 11 girls, all of whom are healthy. The only maternal uncle and the maternal grandmother are healthy.
Isolation and characterization ofgp39 cDNAs. PBMCs were isolated from heparinized whole blood by centrifugation over lymphocyte separation medium (Organon Teknika Corp., Durham, NC). Cells were washed twice in RPMI 1640 and cultured under standard conditions (370C, 6% C02) in RPMI 1640 containing 10% fetal calf serum (HyClone Laboratories), 100 U/ml penicillin and 100 Mg/ml streptomycin. Cells were activated in the presence of PMA (10 ng/ml) and ionomycin (1 yg/ml) for 8 h. 107 cells were pelleted and immediately lysed in 0.5 ml lysis buffer (4 M guanidinium thiocyanate, 25 Reactions were incubated at 420C for 3.5 h, then heated to 100°C for 10 min, and placed on ice. PCRs were performed using Pfu polymerase (Stratagene, La Jolla, CA) or Taq polymerase (Perkin-Elmer Corp., Norwalk, CT) according to the manufacturers recommendations using oligonucleotide primers at the 5' and 3' ends of the coding region as previously described (6) . As a template, 0.1 or 1 M1 of the cDNA reaction mixture was used. PCR products from affected males were sequenced directly following asymmetric PCR as described previously (6) . PCR 
Results
Pedigree analysis offamilies with HIGMJ. As previously reported, the index case (C.D.) of Family I (Fig. 1 A) has two point mutations, at positions 405 and 407 of the gp39 cDNA, which result in substitution of two amino acids and the inability of the mutated gp39 to bind to its ligand CD40, and a silent polymorphism at position 169 as compared with the original gp39 sequence (6, 15) . DNA sequencing of multiple independent cDNA clones encoding gp39 from members of Family 1 indicated that both C.D.'s mother (K.H.) and sister (D.R.) are carriers of HIGM 1 and express genes corresponding to the wild type and the defective gp39, while the maternal grandmother (W.H.) expresses only the wild-type gene and is not a carrier. For K.H., 9 of 12 independent gp39 cDNA clones encoded the wild type sequence, while for D.R., only 4 of 14 independent gp39 cDNA clones were wild type. In both instances the defective gene carried the gp39 polymorphism at position 169. DNA sequencing analysis of the maternal grandmother showed that she carries two wild type gp39 genes, one with the polymorphism of C.D. (10 of 18 independent cDNA clones) and one without (8 of 18 independent cDNA clones). Similar analysis of the cDNAs encoding gp39 from the maternal grandfather indicated that he carries a gp39 gene which contains the polymorphism (4 of 4 independent cDNA clones). These data suggest that the mother inherited the polymorphic allele from her father and the defect is a paternally derived de novo mutation arising in the mother, K.H. The index case of Family 2, J.W., has a point mutation at position 724 resulting in a single amino acid substitution, and the same silent polymorphism at position 169 as found in C.D. (15) . J.W.'s mother, J.S., is an obligate carrier having two affected male offspring (Fig. 1 B) . Sequencing of gp39 cDNAs derived from mRNA isolated from in vitro stimulated PBMCs from J.S. demonstrated the presence of both alleles, the wild type and mutant, and the polymorphism at position 169 was found on the mutant allele. The low frequency of the mutant clones suggested that her T cells predominantly express the wild type gp39 gene (47 of 48 independent cDNA clones were wild type). J.W.'s maternal grandfather, M.J., carries a gene which contains the polymorphism at position 169 (7 of 7 independent clones). This suggests that the defect in this family is also a paternally derived de novo mutation. The maternal grandmother was not available for analysis.
Using PCR and DNA sequencing, we have identified the gp39 defect in a third family (Family 3, Fig. 2 A) . In this family, the mutation consists of a 63-base pair deletion that results in an inframe deletion of 21 amino acids within the TNF homologous extracellular domain of gp39 (Fig. 2 B) . This mutation is the 404-309-242- same defect previously reported in an unrelated case (21) . The large deletion allowed the use of a PCR-based approach for the identification of affected males and female carriers in this family. PCR reactions of cDNA derived from the activated PBMC of the affected males yielded fragments significantly smaller than those obtained for the normal control and of the size expected based on the 63-bp deletion. A similar analysis of the mother, C.C., an obligate carrier, and one daughter, J.C., revealed two gp39 DNA fragments consistent with the presence of a wild-type and a mutant gene (Fig. 2 B) . The carrier status of the second daughter, R.C.3, is not described at the family's request. This PCR based approach does not permit an evaluation of which gene, wild type or defective, is preferentially expressed.
Cell surface expression of functional gp39 by activated T cellsfromfemale carriers. The DNA sequencing data described above indicate that T cells in which the normal X chromosome is active are not preferentially selected in female carriers of X-HIM. To determine if the proportion of activated T cells 618 Hollenbaugh et al. Log Fluorescence Figure 3 . (Fig. 3 B) . R., C.C., and J.C., respectively; Of CD69+ cells, 66, 63, 57, 38%, are gp39-). However, for the carrier J.S., no significant difference from the normal control could be detected ( Fig. 4 ; 73% of CD3+ cells and 81% of CD69+ cells are gp39+).
Piscussion
The subject of chromosomal inactivation in HIGM1 has been controversial. Reports showing preferential inactivation of the mutated X chromosome in lymphocytes of female carriers as well as reports demonstrating a random pattern of X chromosome inactivation in obligate carriers have appeared in the literature (1, 25, 26) . These conflicting reports may be due to the heterogeneity of the hyper IgM syndrome. The molecular characterization of HIGM1, demonstrating that mutations in the T cell surface protein gp39 are the basis for the has allowed the reexamination of the pattern of inactivation in the lymphocytes of female carri Using nucleic acid sequencing, PCR analysis, ano ing studies we have obtained detailed family pe affected families. This has allowed us to identi female carriers of the defective gene. Messenger gp39 was isolated from the in vitro activated I female carriers from two different families and cDNA. Multiple independent cDNA clones enco each carrier were sequenced. These experiment the pattern of X chromosome inactivation in tl these female carriers was quite heterogeneous. ined the levels of functional gp39 protein ex surface of the in vitro activated T cells obtain carriers from these two families and found th functional gp39 correlated very well with the n clones encoding wild-type gp39. A third fami fected males was also analyzed. DNA sequencih the mutation responsible for the defect in this fa amino acid deletion in the extracellular domaii large deletion allowed the development of a PC for the rapid detection of the mutation in other f Although this method does not allow a deter degree of skewing of the X chromosome inactiv the facile identification of female carriers. An members studied, two female carriers were iden tion of the T cells of these female carriers sA express the normal and the mutated gene at appr levels. These observations support the previou suggest that in lymphocytes of female carriers tt ential selection for T cells in which the normal is active. Because of the random inactivation of the carrying the defect, this could not be used t carriers as has been suggested for detection of e XSCID and Wiskott-Aldrich syndrome (27) (28) (29) K.H. history of female carriers of X-linked immunodeficiencies may )n that was CD33.
provide important information on the pathobiology of the disease and on the role of the gene product in the immune response. Extreme Lyonization may result in the phenotypic expression HIGM1 defect, of an X-linked disease in a female carrier as evidenced by cases X chromosome of hemophilia A, Wiskott-Aldrich syndrome and Duchenne iers of HIGM1. muscular dystrophy observed in females (30) (31) (32) (33) . In the case d receptor bindof HIGM1, female carriers are asymptomatic and serum levels digrees of three of immunoglobulins are within normal ranges, despite low numify a number of bers of T cells expressing gp39 (< 30%). This suggests symp-RNA encoding toms of X-HIM are prevented by the presence of a small per-PBMC of three centage of T cells able to express functional gp39. The role of used to prepare the CD40/gp39 interaction in antibody production suggests this ding gp39 from may be a potential therapeutic target in the treatment of antits indicated that body-mediated autoimmunity. The lack of a phenotypic effect he T cells from of severely reduced levels of gp39 in female carriers of HIGM 1 We also examsuggests that a very high level of inhibition of the gp39/CD40 cpressed on the interaction would be necessary for effectiveness. Preliminary ed from female in vivo studies have shown that onset of collagen induced arthriiat the levels of tis could be prevented in a murine model by the administration umber of cDNA of anti-gp39 monoclonal antibody (34) . These results suggest ly with five afthat in the pathological condition, sufficient inhibition of the ng revealed that interaction can be achieved and that inhibitors of the gp39/ imily was a 21 -CD40 receptor ligand pair have therapeutic potential in the n of gp39. This treatment of autoimmune diseases. R based method
The pattern of X chromosome inactivation in female carriers amily members.
of X-linked diseases may provide information on the role the mination of the affected gene plays in lymphocyte development. For example, ation, it allowed the X chromosome carrying the defective gene is inactivated in nong the family B cells of carriers of XLA (35) , and B and T cells of carriers itified. Examinaof X-linked SCID (29) . This unilateral pattern of X chromosome iowed that they inactivation reflects the disadvantages conferred on the cells -oximately equal that express the defective gene during differentiation and prolifis reports which eration. Indirect evidence has implicated the gp39/CD40 interiere is no preferaction in T cell development. CD40 is expressed by thymic X chromosome epithelial cells and anti-CD40 mAb in the presence of INF--y or IL-l triggers the release of GM-CSF (12) . However, in vitro X chromosome activated thymocytes did not bind to CD40-Ig suggesting that lo detect female they lack expression of gp39 (C. P. Edwards and C. B. Wilson, carriers of XLA, personal communication). Although additional experiments are i). As an altemaneeded to elucidate the role, if any, of gp39 in T cell develop-ment, the lack of preferential inactivation of the mutated X chromosome in the T cells of female carriers of HIGM1 suggests that expression of gp39 during T cell ontogeny is not critical for T cell development. The identification of the defect in the X-HIM syndrome as a defect in the gene encoding gp39 allows a comparison of known roles of the receptor ligand pair with the clinical manifestations of the disease. The importance of the CD40 ligand/ receptor pair in the interaction between B and T cells has been suggested by in vitro experiments. Through the use of mAb, stimulation of the CD40 receptor was found to induce B cell proliferation and isotype switching in the presence of an appropriate costimulus. The absence of isotype switching in the X-HIM patients confirms this role of the gp39/CD40 ligand receptor pair. The recent identification of CD40 on the surface of monocytes, and the resulting cytokine induction when the receptor is engaged, demonstrates another role for the ligand pair (10) . The increased frequency of P. carinii infection and malignancies, generally considered to be a consequence of a T cell defect, may be a result of the lack of monocyte-derived T cell stimulation. The neutropenia observed in some X-HIM patients may also be caused indirectly, by the absence of cytokines normally produced in response to CD40 stimulation, as there is no known direct role of gp39 in the ontogeny or maintenance of this cell population. A recent report has demonstrated that B cell apoptosis upon antigen stimulation is prevented by CD40 costimulation, suggesting a role for CD40 during the elimination of self reactive B cells (36) . In the absence of CD40 stimulation, all B cells might be expected to be eliminated. As the HIM patients have normal numbers of functionally active B cells, a mechanism other than CD40/gp39 interaction must be available for the prevention of apoptosis.
